- Home
- CVR vs BIAF Comparison
CVR vs BIAF Comparison
Compare CVR & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVR
- BIAF
- Stock Information
- Founded
- CVR 1920
- BIAF 2014
- Country
- CVR United States
- BIAF United States
- Employees
- CVR N/A
- BIAF N/A
- Industry
- CVR Industrial Machinery/Components
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CVR Industrials
- BIAF Health Care
- Exchange
- CVR Nasdaq
- BIAF Nasdaq
- Market Cap
- CVR 14.9M
- BIAF 12.2M
- IPO Year
- CVR N/A
- BIAF 2022
- Fundamental
- Price
- CVR $13.90
- BIAF $0.37
- Analyst Decision
- CVR
- BIAF Strong Buy
- Analyst Count
- CVR 0
- BIAF 1
- Target Price
- CVR N/A
- BIAF $6.00
- AVG Volume (30 Days)
- CVR 1.6K
- BIAF 132.0K
- Earning Date
- CVR 03-27-2025
- BIAF 03-31-2025
- Dividend Yield
- CVR 0.86%
- BIAF N/A
- EPS Growth
- CVR N/A
- BIAF N/A
- EPS
- CVR N/A
- BIAF N/A
- Revenue
- CVR $29,663,473.00
- BIAF $9,367,785.00
- Revenue This Year
- CVR N/A
- BIAF $285.51
- Revenue Next Year
- CVR N/A
- BIAF $20.05
- P/E Ratio
- CVR N/A
- BIAF N/A
- Revenue Growth
- CVR N/A
- BIAF 2813.87
- 52 Week Low
- CVR $13.40
- BIAF $0.26
- 52 Week High
- CVR $22.27
- BIAF $3.16
- Technical
- Relative Strength Index (RSI)
- CVR 36.55
- BIAF 26.22
- Support Level
- CVR $13.40
- BIAF $0.26
- Resistance Level
- CVR $14.79
- BIAF $0.47
- Average True Range (ATR)
- CVR 0.44
- BIAF 0.10
- MACD
- CVR -0.04
- BIAF -0.03
- Stochastic Oscillator
- CVR 28.09
- BIAF 18.74
About CVR Chicago Rivet & Machine Co.
Chicago Rivet & Machine Co is in the fastener industry in North America. The company operates in two segments namely fasteners and assembly equipment. Its fastener segment consists of the manufacture and sale of rivets, cold-formed fasteners, parts, and screw machine products. The assembly equipment segment consists mainly of the manufacture of automatic rivet setting machines, automatic assembly equipment, and parts and tools for such machines. The majority of revenue is from the fastener segment. Geographically, the majority is from the United States.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.